



A HEART FOR LIFE

Medicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company's vision is to become a leading specialty pharmaceutical company in the commercialization and development of unique small molecule pharmaceuticals in the cardiovascular and neurological fields for unmet medical needs.

### LEAD PRODUCTS

- 1 AGGRASTAT® - US GP IIb/IIIa inhibitor market - \$400 million (AGGRASTAT + two competitors)  
Product website: [www.medicure.com/aggrastat](http://www.medicure.com/aggrastat)
- 2 TARDOXAL™ – in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet need

### MANAGEMENT

Albert D. Friesen, Ph.D., CEO  
Dawson J. Reimer, MAES, President & COO  
James Kinley, CA, CFO

### CAPITAL STRUCTURE

182,947,595 shares issued

Medicure is focused on growing revenues through its US sales and marketing subsidiary, Medicure Pharma Inc., and building value from other R&D initiatives. Medicure's commercial business is focused on Aggrastat, one of three products competing within the >US\$400 million market for GP IIb/IIIa inhibitors, a cardiovascular product for treatment of Acute Coronary Syndromes. The primary focus of Medicure's R&D activities is the clinical development of TARDOXAL in the treatment of dyskinesias and other movement related disorders.

### GROWTH AND REVENUE

To build and maximize shareholder value through:

- 1 Increasing Commercial Revenue from AGGRASTAT sales
- 2 Development of TARDOXAL through Phase II for partnering

### FISCAL 2011 NET SALES

CON \$3.6 Millon

MPH: TSX-V



### MEDICURE INC.

2-1250 Waverley Street  
Winnipeg, Manitoba,  
CANADA R3T 6C6

### CONTACT

Dawson J. Reimer, MAES  
President & COO  
[dreimer@medicure.com](mailto:dreimer@medicure.com)  
888.435.2220 ext. 323

[www.medicure.com](http://www.medicure.com)

